10 Sep, 2021
Genor Announces GB226 Clinical Data to Be Presented at ESMO 2021

Genor Biopharma (Stock code: 6998.HK) announced today that the latest clinical data on Geptanolimab (GB226) would be presented at ESMO (European Society for Medical Oncology) Congress 2021.


Dr. SHI Yuankai, M.D. Professor of Medical Oncology Department of Medical Oncology Deputy Director of National Cancer Center, Vice President of Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, will orally present the clinical data on September 19 (CEST). The clinical trial to be presented is designed to evaluate the efficacy and safety of Geptanolimab monotherapy in relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL).



831MO - Geptanolimab(GB226in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial